Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions
What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?
0:58
May 7, 2026Psoriasis

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?

-

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?
1:12
May 7, 2026Psoriasis

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?

-

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?
1:28
May 7, 2026Psoriasis

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?

-

Are there particular comorbidity profiles where apremilast feels especially appropriate?
1:40
May 7, 2026Psoriasis

Are there particular comorbidity profiles where apremilast feels especially appropriate?

-

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?
0:38
May 7, 2026Psoriasis

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?

-

What lifestyle or occupational factors make oral therapy particularly appealing?
1:26
May 7, 2026Psoriasis

What lifestyle or occupational factors make oral therapy particularly appealing?

-

How do you document quality-of-life impact in vitiligo or atopic dermatitis?
1:52
May 4, 2026Atopic Dermatitis

How do you document quality-of-life impact in vitiligo or atopic dermatitis?

-

Which clinical metrics carry the most weight with payers?
1:12
May 4, 2026Atopic Dermatitis

Which clinical metrics carry the most weight with payers?

-

How do you justify nonsteroidal therapy after steroid failure?
1:12
May 4, 2026Atopic Dermatitis

How do you justify nonsteroidal therapy after steroid failure?

-

When is a peer-to-peer review worth pursuing?
1:25
May 4, 2026Atopic Dermatitis

When is a peer-to-peer review worth pursuing?

-

How do you document medical necessity for ruxolitinib in mild-to-moderate disease?
1:14
May 4, 2026Atopic Dermatitis

How do you document medical necessity for ruxolitinib in mild-to-moderate disease?

-

When is step therapy inappropriate before ruxolitinib cream?
1:11
May 4, 2026Atopic Dermatitis

When is step therapy inappropriate before ruxolitinib cream?

-

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?
1:25
Apr 13, 2026Psoriasis

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

-

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?
1:51
Apr 13, 2026Psoriasis

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

-

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?
2:04
Apr 13, 2026Psoriasis

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

-

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?
2:34
Apr 13, 2026Psoriasis

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

-

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?
2:55
Apr 13, 2026Psoriasis

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

-

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?
1:29
Apr 13, 2026Psoriasis

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

-

When apremilast first launched, how was it positioned, and what do we understand differently now?
1:55
Apr 13, 2026Psoriasis

When apremilast first launched, how was it positioned, and what do we understand differently now?

-

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?
0:50
Apr 2, 2026Atopic Dermatitis

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

-

When do bridge programs make the most clinical sense for patients?
0:35
Apr 2, 2026Atopic Dermatitis

When do bridge programs make the most clinical sense for patients?

-

How do you document treatment goals when requesting newer therapies?
0:36
Apr 2, 2026Atopic Dermatitis

How do you document treatment goals when requesting newer therapies?

-

How do you document medical necessity when disease severity seems borderline?
1:03
Apr 2, 2026Atopic Dermatitis

How do you document medical necessity when disease severity seems borderline?

-

What clinical language resonates most with payers during prior authorization review?
1:07
Apr 2, 2026Atopic Dermatitis

What clinical language resonates most with payers during prior authorization review?

-